The Discoidin Domain Containing Receptor 2 pipeline drugs market research report outlays comprehensive information on the Discoidin Domain Containing Receptor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Discoidin Domain Containing Receptor 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Central Nervous System which include the indications Solid Tumor, Gastric Cancer, Alzheimer’s Disease, and Parkinson’s Disease. It also reviews key players involved in Discoidin Domain Containing Receptor 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Discoidin Domain Containing Receptor 2 pipeline targets constitutes close to seven molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, and Phase I stages are 2, 1, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 3 molecule.
Discoidin Domain Containing Receptor 2 overview
Discoidin domain-containing receptor 2, also known as CD167b (cluster of differentiation 167b), is a protein that in humans is encoded by a gene DDR2. It belongs to a member of the discoidin domain receptor subclass of the receptor tyrosine kinase (RTKs) protein family. RTKs play a key role in the communication of cells with their microenvironment. The encoded protein is a collagen-induced receptor that activates signal transduction pathways involved in cell adhesion, proliferation, and extracellular matrix remodeling. This protein is expressed in numerous cell types and may also be involved in wound repair and regulate tumor growth and invasiveness. Mutations in this gene are the cause of short limb-hand type spondylometaepiphyseal dysplasia.
For a complete picture of Discoidin Domain Containing Receptor 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
